Steffen Koschmieder

1 month ago | nature.com | Kirsi Manz |Florian H. Heidel |Steffen Koschmieder |Frank Stegelmann |Andreas Hochhaus |Haifa Kathrin Al-Ali | +3 more

AbstractMyeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients’ quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking.

Nov 19, 2024 | academic.oup.com | RWTH Aachen |Martin Grasshoff |Steffen Koschmieder

The development of single-cell RNA-sequencing (scRNA-seq) methods allows the characterization of transcriptional changes in yet poorly characterized cell types [1, 2]. This has been crucial to uncover cellular mechanisms related to diseases [3–6]. Clonal selection, i.e. the expansion of particular cell populations with malignant mutations, is a crucial mechanism in tumor cell development [7].

Nov 5, 2023 | nature.com | Martin Zenke |Steffen Koschmieder

Dear Editor,Myeloproliferative neoplasms (MPNs) are caused by somatic driver mutations, such as JAK2V617F, which might also affect cellular aging and senescence. Here, we analyzed the heterogeneity of aging in MPN patients and if this can be used to specifically target malignant cells. Our results indicate that cellular aging is accelerated in malignant MPN clones and this can provide a target for treatment with senolytic drugs or telomerase inhibitors.